WS #16446
Eli Lilly announced positive Phase 3 results for retatrutide, a triple agonist showing superior A1C reduction and weight loss compared to Ozempic in Type 2 diabetes patients. This is a significant catalyst for LLY, potentially expanding its addressable market beyond obesity into diabetes care. Conversely, Pfizer's halt of two Phase 2 arms for its breast cancer trial and Boston Scientific's plunge highlight the binary risks in the broader healthcare sector, where innovation leaders like Lilly are decoupling from sector-wide volatility.
Healthcare Innovation
Eli Lilly announced positive Phase 3 results for retatrutide, a triple agonist showing superior A1C reduction and weight loss compared to Ozempic in Type 2 diabetes patients. This is a significant catalyst for LLY, potentially expanding its addressable market beyond obesity into diabetes care. Conversely, Pfizer's halt of two Phase 2 arms for its breast cancer trial and Boston Scientific's plunge highlight the binary risks in the broader healthcare sector, where innovation leaders like Lilly are decoupling from sector-wide volatility.